BU and CY (BU/CY; 200 mg/kg) before HLA-matched sibling allo-SCT in children with sickle cell disease (SCD) is associated with 85% EFS but is limited by the acute and late effects of BU/CY myeloablative conditioning. Alternatives include reduced toxicity but more immunosuppressive conditioning. We investigated in a prospective single institutional study, the safety and efficacy of a reduced-toxicity conditioning (RTC) regimen of BU 12.8-16 mg/kg, fludarabine 180 mg/m 2 , alemtuzumab 54 mg/m 2 (BFA) before HLA-matched sibling donor transplantation in pediatric recipients with symptomatic SCD. Eighteen patients, median age 8.9 years (2.3-20.2), M/F 15/3, 15 sibling BM and 3 sibling cord blood (CB) were transplanted. Mean whole blood and erythroid donor chimerism was 91% and 88%, at days +100 and +365, respectively. Probability of grade II-IV acute GVHD was 17%. Two-year EFS and OS were both 100%. Neurological, pulmonary and cardiovascular function were stable or improved at 2 years. BFA RTC and HLA-matched sibling BM and CB allo-SCT in pediatric recipients result in excellent EFS, long-term donor chimerism, low incidence of GVHD and stable/improved organ function.
INTRODUCTION
Sickle cell disease (SCD) is a chronic, debilitating disorder characterized by acute episodes of extreme pain ('crises'), hemolytic anemia and chronic damage to vital organs, resulting in poor quality of life and a shortened life span. [1] [2] [3] [4] The only known curative therapy is an allo-SCT. [5] [6] [7] [8] Historically, most centers have used myeloablative conditioning (MAC) with BU (14 mg/kg) and CY (BU/CY; 200 mg/kg) using BM as the stem cell source. Following BU/CY and HLA-matched sibling allo-SCT in patients with high-risk SCD, probabilities of TRM, graft failure and EFS range between 5-10%, 7-10% and 82-86%, respectively. 7, 8 Locatelli et al. 9 compared the results of patients with SCD undergoing allo-SCT with BM to those with umbilical cord blood (UCB) and found the 6-year EFS to be 92% and 90%, respectively, supporting the curative potential of both stem cell sources. A major limitation to MAC conditioning followed by allo-SCT is long-term organ dysfunction. [10] [11] [12] An alternative is to utilize reduced-toxicity conditioning (RTC) regimens to decrease the risk of TRM. 13, 14 This is defined as a regimen associated with myeloablation but associated with reduced toxicity secondary to conditioning. 15 Non-ablative conditioning regimens for SCD have also been studied. Recently, Hsieh et al. reported the results of a pilot study utilizing 300 cGy TBI and alemtuzumab in 10 adult patients with high-risk SCD and demonstrated a 90% EFS but a 10% incidence of graft failure. However, patients required long-term immunosuppression and had only 50% T-cell donor chimerism at 1 year. 16 We report in this prospective pilot study, the safety and efficacy of an RTC regimen followed by allo-SCT utilizing HLA-matched sibling BM or sibling UCB units in children and adolescents with SCD.
PATIENTS AND METHODS

Patients and eligibility
Patients ⩽ 21 years of age with homozygous Hb S disease (HbSS), sickle-Hb C disease (HbSC), sickle beta-plus-thalassemia (HbS/β + ) or sickle beta-zerothalassemia (HbS/β 0 ) were eligible if they had an HLA-matched sibling BM donor or UCB unit, with a total nucleated cell dose of 5.0 × 10 7 /kg (pre thaw). Eligibility requirements included: a history of two or more vaso-occlusive pain crises/year requiring narcotics, priapism, acute chest syndrome, splenic sequestration, stroke, transient ischemic attacks, abnormal transcranial Doppler, sickle nephropathy, aplastic crisis, RBC alloimmunization, osteonecrosis, retinopathy with vision changes, or two of the following: Hgb o7 g/dL, early dactylitis (o 1 year) and WBC >20 × 10 9 /L. Patients were required to demonstrate adequate organ function as we have previously defined. 15, 17 All patients and parents signed informed consent and assent (patients >7 years). This research study was approved by Columbia University Medical Center Institutional Review Board and is registered on www.clinicaltrials.gov as NCT00408447.
HLA typing
HLA-A and HLA-B antigen typing was performed by intermediate resolution molecular testing and HLA-DRB1 allele typing was determined by hybridization of PCR-amplified DNA with sequence-specific oligonucleotide probes as we have previously described. 17 Seventeen patients received a BFA conditioning regimen consisting of BU (3.2-4 mg/kg/day i.v. divided b.i.d., days − 8 to − 5), fludarabine (30 mg/m 2 /day, days − 8 to − 3) and alemtuzumab (2 mg/m 2 day − 6, 6 mg/m 2 days − 5, − 4 and 20 mg/m 2 days − 3, − 2; 54 mg/m 2 total dose, days − 6 to − 2) as we have previously described. 15 BU pharmacokinetic studies were performed for all patients with a target steady state concentration (C ss ) of 600-900 ng/mL. 17, 18 For patient 13, melphalan (70 mg/m 2 /day, days − 8 and − 7) was substituted for BU due to the development of respiratory distress with the first dose of BU.
Seizure prophylaxis consisted of phenytoin or levetiracetam ± lorazepam during BU administration and was continued through discontinuation of tacrolimus. Additional measures included: magnesium levels >2.0 mg/dL, Hb concentrations >8 gm/dL and platelet counts >30 000/μL. 8 
GVHD prophylaxis and grading
Acute GVHD (aGVHD) prophylaxis consisted of tacrolimus and mycophenolate mofetil (MMF). 21, 22 Tacrolimus 0.03 mg/kg/day continuous i.v. infusion or 0.12 mg/kg orally (PO) twice a day was started (dose adjusted to maintain blood levels of 10-20 ng/mL) on day − 8. 19 MMF was administered at 900 mg/m 2 q6-8 h PO or i.v. starting on day +1. 19, 20 MMF was tapered if patients had ⩽ grade II aGVHD on day +180 and tacrolimus was tapered upon conclusion of the MMF taper. 19, 20 aGVHD and chronic GVHD (cGVHD) were graded according to Seattle consensus criteria. 21 Supportive care and infection prophylaxis Sargramostim (250 μg/m 2 /day) was started i.v. daily from day +7 or when the ANC was o0.5 × 10 9 /L post infusion, whichever came first, until the ANC reached ⩾ 0.3 × 10 9 /L for 2 days and then switched to filgrastim (10 μg/kg/day) i.v. or subcutaneously until an ANC ⩾ 2.5 × 10 9 /L was achieved for 3 days. 22 Herpes simplex prophylaxis was acyclovir (250 mg/m 2 ) i.v. q8 h from day − 5 until engraftment. Pneumocytis jirovecii pneumonia prophylaxis consisted of trimethoprim/sulfamethoxazole or i.v. pentamidine until day − 2 and then resumed after myeloid engraftment. Fungal and CMV prophylaxis was administered as previously described. 23, 24 Engraftment and donor chimerism Neutrophil recovery was defined as an ANC of 0.5 × 10 9 /L for three consecutive days. Platelet recovery was defined as a platelet count of 20 × 10 9 /L independent of platelet transfusions for seven consecutive days. Primary myeloid graft failure was defined as failure to achieve a donorderived ANC ⩾ 0.5 × 10 9 /L by day +42 (day +60 for UCB recipients) and/or ⩽ 50% whole blood donor chimerism by day +60. Donor whole blood and erythroid (CD71) donor chimerism was measured on days +30, 60, 100, 180, 365 and 730 (±10 days) using a semiquantitative method to measure the amplification products of genes containing STRs. 15, 25 Immune reconstitution Absolute lymphocyte subset counts were measured pre-allo-SCT and at days +30, 60, 100, 180, 365 and 730 (±10 days).
Hb electrophoresis
Quantitative Hb electrophoresis was performed pre-allo-SCT and at days +30, 60, 100, 180, 365 and 730 (±10 days).
Organ function
The following organ function testing was performed pre-allo-SCT and on days +365 and 730 (±10 day) post allo-SCT: 26 EFS time was defined as the time between transplantation and disease progression or death due to any cause, and was censored if patients were alive without the events at the day of last follow-up. OS time was the time between transplantation and death due to any cause, and was censored if patients were alive at the day of last follow-up.
Statistical considerations
Continuous variables were summarized as medians and ranges or means ± s.d. and categorical variables as percentages. The probabilities of neutrophil engraftment, plt engraftment, ⩾ grade II aGVHD and cGVHD were estimated using the Kaplan-Meier product limit method. Boxplots were used to illustrate the patterns of percent whole blood chimerism, percent CD71 subset donor chimerism, HbS percentages and various absolute lymphocyte subset counts over 2 years of post transplant followup. Continuous variables were compared between two groups using twotailed t-tests. The two-tailed paired t-test was used to assess the changes in pulmonary function. A P-value o0.05 was considered significant. The analysis was carried out with SAS 9.2 and the plots were generated in R software (SAS Institute Inc.100 SAS Campus Drive, Cary, NC, USA).
RESULTS
Patient characteristics
Eighteen patients underwent an HLA-matched sibling allo-SCT including 10 HbSS, 4 HbSC, 2 HbS/β 0 and 2 HbS/β + . There were 15 males and 3 females. The median age of the patients at allo-SCT was 8.9 years (range 2.3-20.2). The median follow-up time was 1065.5 days for all patients (range 135-2731). Coexisting conditions and indications for allo-SCT and prior medical therapy are summarized in Table 1 .
Patients underwent allo-SCT from either sibling BM (n = 15) or sibling UCB (n = 3). Donor sources and HLA matching are listed in Table 1 . For recipients of sibling BM, the median total nucleated cell dose/kg was 6.54 × 10 8 (range 2.27-11.31) and the median CD34 cell dose/kg was 5.43 × 10 6 (range 1.50-15.38). For recipients of sibling UCB, the median total nucleated cell dose/kg was 3.6 × 10 7 (range 3.4-7.9) and the median CD34 cell dose/kg was 2.9 × 10 5 (range 2.1-3.6). The mean BU C ss was 658.7 ± 167.5 ng/mL following the first dose of BU with seven patients requiring adjustments. Engraftment and donor chimerism All patients engrafted neutrophils at median day 16 (range 0-41) and platelets at median day 24.5 (range 0-75).
Patients achieved mean whole blood donor chimerism of 86%, 91%, 91%, 92%, 88% and 93%, at days +30, 60, 100, 180, 365 and 730 post allo-SCT, respectively (Figure 1c ). Mean donor chimerism in the erythroid (CD71) subset at these time points was 88%, 87%, 89%, 88%, 86% and 91%, respectively (Figure 1d ). No patient received either a DLI or stem cell boost. 
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Sinusoidal obstructive syndrome No patient in this cohort developed sinusoidal obstructive syndrome of the liver.
Acute and chronic GVHD The incidence of grade II-IV aGVHD was 17% (n = 3) and of grade III-IV aGVHD was 11% (n = 2) (Figure 2a ). The incidence of cGVHD was 11% (n = 2) (Figure 2b ), and this resolved in both patients.
Percent HbS
Donor genotype was predictive of HbS percentages in recipients post transplant. All patients with non-sickle trait donors (HbAA or HbAC) had stable engraftment and ultimately achieved median HbS levels of 1.2% and 1.4% at 1 and 2 years post transplant, respectively. In the eight patients undergoing allo-SCT from sickle trait donors, five and four patients were evaluable at 1 and 2 years, respectively, and demonstrated a median HbS of 38% and 39%, respectively, consistent with the donor genotype.
Organ function
Neurologic. Fourteen of the eighteen patients have been followed for >1 year post transplant and 12 for >2 years. Two patients had evidence of stroke on pre-allo-SCT MRI and experienced no worsening of their neurological status, with no further MRI changes. One patient (patient 13) developed an Table 2 . By day +730, all evaluable patients had still not returned to their pre-allo-SCT levels. Viral and fungal infections Four patients had CMV reactivation with one of the four developing CMV pneumonitis and colitis. All developed CMV in the first 60 days post allo-SCT and all patients were treated and resolved of their CMV reactivation and disease. Two patients had upper respiratory tract infections with respiratory syncytial virus at days 51 and 124 post allo-SCT, respectively, that resolved without treatment. There were no other viral infections and no fungal infections.
EFS and OS All patients in this series remain alive with donor engraftment following HLA-matched sibling allo-SCT. EFS and OS are 100% (Figure 4) .
DISCUSSION
This study represents one of the largest prospective single center cohorts of pediatric recipients with SCD undergoing RTC followed by allo-SCT using either matched sibling BM or UCB. In those patients receiving a matched sibling donor SCT (BM or UCB), the OS and EFS were 100% and 100%, respectively. This compares favorably to results previously described with MAC with BU and 200 mg/kg of CY and allo-SCT using HLA-matched sibling BM donors. 5, 7, 8 aGVHD and cGVHD are major causes of nonrelapse morbidity and mortality, affecting 40-60% patients post allo-SCT for malignant conditions. 27, 28 We observed an incidence of grade II-IV aGVHD in 17% and cGVHD in 11% of patients. Although the sample size is small, these results are comparable to those seen in children and adolescents with SCD after MAC and lower than the incidence in those with malignant conditons. 5, 7, 8, [27] [28] [29] [30] [31] Methods to decrease GVHD are paramount, especially since many of the patients in this cohort had less severe disease.
In all but one patient over day +180, whole blood and RBC (CD71) chimerism was determined to be over 85%, which was sustained even after withdrawal of immunosuppression. These erythroid donor chimerism results are similar to those reported by Krishnamurti et al. 29 following reduced-intensity conditioning with BU, fludarabine, equine anti-thymocyte globulin and total lymphoid irradiation. Walters et al. 32 reported the results of mixed donor chimerism after BU/CY conditioning and HLA-matched sibling BMT in children with SCD and noted 13/50 patients who had stable mixed donor chimerism of o 99%. The 1-and 2-year Hb electrophoresis results from AA and AS HLA-matched sibling donors in our study are similar to those reported by Krishnamurti et al. 29 We previously compared the incidence of systemic viral infection and invasive fungal infection following BU/CY vs BFA conditioning post allo-SCT and found no increase of systemic opportunistic infections following BFA conditioning. 26 In this study, we observed slow recovery of T cells (CD3 With respect to pulmonary function, stability and improvement were observed at 2 years post allo-SCT, similar to the results that have been reported by Walters et al. 11 following BU/CY conditioning and sibling BMT in pediatric recipients with SCD. Furthermore, stability in the pulmonary function tests post allo-SCT also suggests that our conditioning regimen did not induce significant long-term pulmonary toxicity post allo-SCT.
PH is a major cause of sudden death in patients with SCD 1 possibly as a result of impaired nitric oxide bioavailability. 2 Cardiac function was assessed at baseline by Doppler echocardiography, with only one patient demonstrating mild PH (TR jet velocity 2.8 m/s). At 1 and 2 years post allo-SCT, no patient exhibited any evidence of PH, including the patients with mild-to-moderate PH at baseline. There was no demonstrable ventricular dysfunction seen (data not shown). These results may, in part, be due to the fact that PH is usually detected in older adolescent and adult patients with SCD and as such these findings are too premature to determine whether allo-SCT confers lifelong protection against PH in patients with SCD.
Central nervous system complications, in particular stroke and transient ischemic attacks, are among the most debilitating complications of SCD. The need for secondary prevention in patients with SCD who have had a previous stroke is critical. 3, 33 In a series studying 137 patients on chronic transfusion therapy for secondary stroke prevention, 31 patients had a second stroke while receiving chronic transfusion therapy. 33 Similar to the results described by Walters et al., 11 our series also showed a stabilizing effect on central nervous system function and prevention of future stroke. However, neurological toxicities due to calcineurin inhibitors can occur following allo-SCT 34, 35 as noted in one patient. Infertility remains a concern for patients with SCD considering allo-SCT. Current studies are underway to assess the effect of BFA conditioning on fertility in males and females. In postpubertal males, semen analysis in conjunction with testosterone, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels are measured. Similarly, in postpubertal females anti-mullerian hormone (AMH), estradiol, LH and FSH levels are evaluated. In summary, this pilot study demonstrates that an RTC regimen of BFA, followed by an HLA-matched sibling BM or UCB allo-SCT can be curative in pediatric recipients with SCD with no sustained long-term toxicities to date. All but one allo-SCT recipient had sustained whole blood and erythroid donor chimerisms >85% and stabilization or improvement in organ function. Certain patients in this study did have relatively few complications before transplantation and did not satisfy the more traditional criteria for severe disease. This, in part, may have contributed to the excellent outcomes seen in this cohort. Perhaps the time has arrived where allo-SCT is offered to children with HLA-matched sibling donors with or without early SCD complications. 36, 37 Limitations to this trial include the small number of patients with limited follow-up. In addition, the authors are aware that alemtuzumab is not readily available to all centers performing allo-SCT for SCD. Alternatives include rabbit anti-thymocyte or total lymphoid irradiation. The attainment of sustained long-term erythroid donor chimerism following BFA conditioning and HLAmatched sibling donor transplantation in this cohort of patients with SCD is promising and based on our results may prompt physicians to extend the application of this treatment to patients with less severe SCD.
